Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 120

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 120
---
 ) |
| Total comprehensive (loss) income                                                 |     |                    |   (441,572 | ) |     |     |     85,714 |   |
| Less: Total comprehensive (loss) income attributable to non-controlling interests |     |                    |     56,908 |   |     |     |    (27,621 | ) |
| Total comprehensive (loss) income attributable to the shareholders of the Company |     |                    |   (498,480 | ) |     |     |    113,335 |   |
| Earnings per share – basic                                                        |     |                    |      (66.2 | ) |     |     |      176.2 |   |
| – diluted                                                                         |     |                    |      (31.9 | ) |     |     |      176.2 |   |
| Weighted average shares outstanding * – basic                                     |     |                    |      7,162 |   |     |     |        615 |   |
| - diluted                                                                         |     |                    |     14,866 |   |     |     |        615 |   |

<div align='center'>67</div>

Year Ended December 31, 2024 Compared with Year Ended December 31, 2023

Revenue

NewGenIvf’s
revenue increased by approximately 5.8% from US$5,136,153 in 2023 to US$5,433,375 in 2024.

IVF treatment services

NewGenIvf’s IVF treatment
service revenue increased by approximately 35.1% from US$4,021,696 in 2023 to 5,433,375 in 2024. This increase was primarily the result
of our continued expansion of clinics in Thailand and clinic in Kyrgyzstan focusing on IVF services.

Surrogacy and ancillary caring services

NewGenIvf’s surrogacy
and ancillary caring services revenue decreased by approximately 100.0% from US$1,114,457 in 2023 to US$ Nil in 2024. This decrease was
primarily the result of temporary cessation of surrogacy business due to the reorganization of Kyrgyzstan business operation.

Cost of revenue

NewGenIvf’s cost of
revenue increased by approximately 4.4% from US$3,454,368 in 2023 to 3,606,481 in 2024.

Cost